- Home
- MRM vs SNTI Comparison
MRM vs SNTI Comparison
Compare MRM & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- SNTI
- Stock Information
- Founded
- MRM 2000
- SNTI 2016
- Country
- MRM Japan
- SNTI United States
- Employees
- MRM N/A
- SNTI N/A
- Industry
- MRM Other Consumer Services
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- SNTI Health Care
- Exchange
- MRM Nasdaq
- SNTI Nasdaq
- Market Cap
- MRM 12.2M
- SNTI 10.4M
- IPO Year
- MRM 2020
- SNTI N/A
- Fundamental
- Price
- MRM $2.70
- SNTI $2.40
- Analyst Decision
- MRM
- SNTI
- Analyst Count
- MRM 0
- SNTI 0
- Target Price
- MRM N/A
- SNTI N/A
- AVG Volume (30 Days)
- MRM 11.0K
- SNTI 16.0K
- Earning Date
- MRM 12-30-2022
- SNTI 11-26-2024
- Dividend Yield
- MRM N/A
- SNTI N/A
- EPS Growth
- MRM N/A
- SNTI N/A
- EPS
- MRM 0.16
- SNTI N/A
- Revenue
- MRM $48,438,179.00
- SNTI $338,000.00
- Revenue This Year
- MRM N/A
- SNTI $254.47
- Revenue Next Year
- MRM N/A
- SNTI $169.66
- P/E Ratio
- MRM $16.64
- SNTI N/A
- Revenue Growth
- MRM N/A
- SNTI N/A
- 52 Week Low
- MRM $2.27
- SNTI $1.52
- 52 Week High
- MRM $8.39
- SNTI $7.43
- Technical
- Relative Strength Index (RSI)
- MRM 42.33
- SNTI 49.58
- Support Level
- MRM $2.42
- SNTI $2.12
- Resistance Level
- MRM $3.07
- SNTI $2.32
- Average True Range (ATR)
- MRM 0.27
- SNTI 0.15
- MACD
- MRM 0.00
- SNTI 0.02
- Stochastic Oscillator
- MRM 31.00
- SNTI 43.18
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.